ACCELERON PHARMA INC (XLRN) is a publicly traded company in the Unknown sector. Across all available filings, 27 corporate insiders have executed 1000 transactions totaling $309.2M, demonstrating a bearish sentiment with -$108.7M in net insider flow. The most recent transaction on Nov 19, 2021 involved a transaction of 98,450 shares valued at $0.
No significant insider buying has been recorded for XLRN in the recent period.
No significant insider selling has been recorded for XLRN in the recent period.
Based on recent SEC filings, insider sentiment for XLRN is bearish with an Insider Alignment Score of 32/100 and a net flow of -$108.7M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at ACCELERON PHARMA INC (XLRN) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 27 insiders are actively trading XLRN stock, having executed 1000 transactions in the past 90 days. The most active insider is Corp /de/ Celgene (Executive), who has made 6 transactions totaling $100.4M.
Get notified when executives and directors at XLRN file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Nov 19, 2021 | J. Dable Habib | Executive | Tender | 98,450 | $N/A | $0 | |
| Nov 19, 2021 | F. Mclaughlin Kevin | Executive | Tender | 10,681 | $N/A | $0 | |
| Nov 19, 2021 | T. Backstrom Jay | Executive | Tender | 21,233 | $N/A | $0 | |
| Nov 19, 2021 | Kango Sujay | Executive | Tender | 18,509 | $N/A | $0 | |
| Nov 19, 2021 | M. Veness Adam | Executive | Tender | 23,423 | $N/A | $0 | |
| Nov 19, 2021 | Nader Francois | Executive | Tender | 6,749 | $N/A | $0 | |
| Nov 19, 2021 | Hamill Laura | Executive | Tender | 474 | $N/A | $0 | |
| Nov 19, 2021 | C. Kearney Terrence | Executive | Tender | 6,749 | $N/A | $0 | |
| Nov 19, 2021 | A. Mccourt Thomas | Executive | Tender | 6,044 | $N/A | $0 | |
| Nov 19, 2021 | L. Smith Karen | Executive | Tender | 1,622 | $N/A | $0 | |
| Nov 19, 2021 | Hite Christopher | Executive | Tender | 930 | $N/A | $0 | |
| Nov 19, 2021 | Malik Kemal | Executive | Tender | 1,622 | $N/A | $0 | |
| Nov 19, 2021 | S. Zakrzewski Joseph | Executive | Tender | 34,499 | $N/A | $0 | |
| Nov 9, 2021 | M. Veness Adam | Executive | Option Exercise | 4,500 | $29.37 | $132.2K | |
| Sep 27, 2021 | Kango Sujay | Executive | Sale | 5,000 | $175.00 | $875.0K | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 574 | $209.0M | 61.9% |
Purchase(P) | 6 | $100.2M | 29.7% |
Exercise(M) | 288 | $25.4M | 7.5% |
Payment(F) | 9 | $1.9M | 0.6% |
Exercise (Options)(X) | 3 | $1.3M | 0.4% |
Tender(U) | 13 | $0 | 0.0% |
Award(A) | 81 | $0 | 0.0% |
Other(J) | 24 | $0 | 0.0% |
Gift(G) | 2 | $0 | 0.0% |
Insider selling pressure at ACCELERON PHARMA INC has increased, with 27 insiders executing 1000 transactions across all time. Total sales of $209.0M significantly outpace purchases of $100.2M, resulting in a net outflow of $108.7M. This selling activity appears largely discretionary, which may warrant closer attention from investors.